Physician profile
Michael A Slusky
NPI 1316075070
$384,210.63
in general payments reported to CMS, 2019-2025
7 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $6,554 · 2021: $24K · 2022: $60K · 2023: $56K · 2024: $73K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $144K · Travel and Lodging: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $9,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $144,377.50 |
| Travel and Lodging | $31,593.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,873.60 |
| Food and Beverage | $9,256.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $382,971.12 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Allergan, INC. | $389.14 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $338.14 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $298.92 | 2022-2025 | Infuse, Btod, Biotrue One Day |
| Abb Con-Cise Optical Group LLC | $104.92 | 2020-2023 | Spectacle Lenses, Contact Lens |
| Abbvie INC. | $58.39 | 2022 | |
| Oyster Point Pharma, INC. | $50.00 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slusky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.